A
ABUS
Arbutus Biopharma Corporation Common Stock
$4.19
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Arbutus Biopharma Corporation Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
$0.78
P/E
5.6
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.02
Nov 11
Posts
No posts about ABUS yet.
About Arbutus Biopharma Corporation Common Stock
Arbutus Biopharma is a Canadian-American biotech company that develops treatments for chronic hepatitis B and for coronaviruses. It has no big product on the market. Its income comes from licensing its drug-delivery technology and from legal settlements and royalties tied to that technology, while the cost of its drug trials is paid from cash on hand.